MIE UNIVERSITY HOSPITAL

Japanese Researchers Launch Final Phase Trial of Bromocriptine for Familial Alzheimer's Disease

- Towa Pharmaceutical and Kyoto University have initiated the final phase of a clinical trial testing bromocriptine, a Parkinson's drug, as a potential treatment for familial Alzheimer's disease using innovative iPS drug discovery methods. - The trial, running until March 2028, will enroll 24 patients with familial Alzheimer's disease caused by specific gene mutations, with preliminary results showing no disease-specific side effects and potential suppression of cognitive decline. - This represents a novel approach to treating early-onset familial Alzheimer's disease, a rare form affecting individuals under 60, for which no cure currently exists despite available symptomatic treatments.